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Abstract
Capsomers were produced in bacteria as glutathione-S-transferase (GST) fusion proteins with human papillomavirus type 16
L1 lacking the first nine and final 29 residues (GST-HPV16L1D) alone or linked with residues 13–47 of HPV18, HPV31 and
HPV45 L2 in tandem (GST-HPV16L1D-L2x3). Subcutaneous immunization of mice with GST-HPV16L1D or GST-HPV16L1D-
L2x3 in alum and monophosphoryl lipid A induced similarly high titers of HPV16 neutralizing antibodies. GST-HPV16L1D-
L2x3 also elicited moderate L2-specific antibody titers. Intravaginal challenge studies showed that immunization of mice
with GST-HPV16 L1D or GST-HPV16L1D-L2x3 capsomers, like CervarixH, provided complete protection against HPV16.
Conversely, vaccination with GST-HPV16 L1D capsomers failed to protect against HPV18 challenge, whereas mice
immunized with either GST-HPV16L1D-L2x3 capsomers or CervarixH were each completely protected. Thus, while the L2-
specific response was moderate, it did not interfere with immunity to L1 in the context of GST-HPV16L1D-L2x3 and is
sufficient to mediate L2-dependent protection against an experimental vaginal challenge with HPV18.
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Introduction
Persistent infection by high risk HPV types is a necessary, but
not sufficient cause of cervical cancer, as well as a significant
fraction of other anogenital cancers and subset of head and neck
cancers [1]. Two licensed HPV vaccines, GardasilH (Merck) and
CervarixH (GSK), are derived from the viral major capsid pro-
tein L1, which assembles into virus-like particles (VLPs) when
expressed in eukaryotic cells [2]. GardasilH is derived from L1
expression in yeast and CervarixH from expression in baculovirus-
infected insect cells. In GardasilH, L1 VLPs derived from HPV6
(20 mg), HPV11 (40 mg), HPV16 (40 mg) and HPV18 (20 mg) are
formulated using an amorphous aluminum hydroxyphosphate
sulphate adjuvant (225 mg). In CervarixH, HPV16 and HPV18 L1
VLPs (20 mg each) are adjuvanted with aluminum hydroxide
(500 mg) and 3-O-desacyl-49-monophosphoryl lipid A (MPL,
50 mg). Both vaccines have demonstrated remarkable protective
efficacy against infection by the specific HPV types present in each
vaccine [3,4,5,6]. Importantly, efficacy has been demonstrated
against the development of low- and high-grade intraepithelial
neoplasia at the cervix, vaginal, vulva and anus that are associated
with HPV16 and HPV18 infection [7]. Vaccination with HPV6
and HPV11 VLPs also prevents the occurrence of benign genital
warts caused by these types [8]. Vaccination with L1 VLPs induces
type-restricted immunity, i.e., near absolute protection against the
type utilized to generate the vaccine, significant but weaker cross-
protection for the most closely phylogenetically-related types (e.g.,
HPV16 and HPV31, or HPV18 and HPV45), and partial to no
protection against more distantly related types or types from other
species [6,9]. HPV16 and HPV18 are associated with 50% and
20% of cervical cancer cases, respectively. Because more than a
dozen high risk types are associated with cervical cancer and
benign genital warts cause significant morbidity, there is an effort
to develop a nonavalent L1 VLP vaccine targeting the seven most
common oncogenic HPV types and the two most common types in
genital warts, HPV6 and HPV11 [10,11].
High-risk HPV infection causes <5% of all cancer worldwide,
but <85% of cervical cancer cases occur in low income countries,
reflecting their lack of resources and infrastructure to support
national cytologic screening efforts [12]. Therefore, the potential
benefits of HPV vaccination are likely to be greatest in low
resource settings, highlighting the need to develop inexpensive and
broadly protective HPV vaccines that can be delivered globally
[2].
VLPs are formed by the assembly of seventy-two capsomers,
and each capsomer is comprised of five L1 molecules [13,14]. L1
capsomers are potential low cost alternatives to VLPs because
they can be purified after expression in bacteria in high yields
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1[15,16,17]. Deletion of the N-terminal 9 amino acids and the C-
terminal 29 amino acids from L1 (herein abbreviated as L1D)
enhances the yield of capsomers [16,18].
Vaccination of dogs with GST-fused canine oral papillomavirus
(COPV) L1 capsomers protects against experimental oral
challenge with COPV [19]. Vaccination with COPV L1 is
completely protective without an adjuvant using only 400 ng
capsomers or 50 ng VLPs. Passive transfer of serum immuno-
globulins from COPV L1 VLP-vaccinated dogs to naı ¨ve recipients
protected the latter from experimental COPV challenge, indicat-
ing the capacity of neutralizing antibody to mediate protection.
Capsomers display comparable type-restricted neutralizing epi-
topes to L1 VLPs [20,21] , but low avidity and broadly reactive L1
epitopes have been described [22]. Because they are not
coordinated with other capsomers and are deleted at both termini,
we hypothesized that L1D capsomers potentially may display
cross-protective epitopes that are otherwise hidden in VLPs and
trigger low avidity broadly protective antibodies difficult to detect
by neutralization assays [23]. Herein we examine the potential of
L1D capsomers to generate antibodies that are both broadly
neutralizing and protective against vaginal challenge.
The need for broad protection against high-risk HPV types can
potentially be provided by multivalent combinations of capso-
mers, but this formulation complicates manufacture. As an
alternative, we explored the C-terminal fusion of the minor
capsid protein L2 to L1D, a site on the capsomer that tolerates
such additions without adversely affecting its structure. Residues
at the amino terminus of L2, including amino acids 13–47
[24,25,26], contain broadly protective epitopes [24,27,28], but
they are weakly immunogenic in comparison to L1 [29,30].
Indeed, when L2 is co-assembled with L1 in a VLP, L2 is
unrecognized by the immune system either because of its internal
positioning or the context of L1 dominant epitopes [29]. We
hypothesized that the tandem fusion of L2 residues 13–47 from
three different and common high-risk HPV types (derived from
HPV18, HPV31 and HPV45 that cause 17.2%, 2.9% and 6.7%
of cervical cancer cases respectively [10]) to the C-terminus of
HPV16 L1D (the type responsible for 53.9% of cervical cancer
cases) would enhance the immunogenicity of L2 by displaying a
dense and regular array of epitopes [31], and thus provide broad
protection (potentially .80%) against cervical cancer using a
single antigen.
Results
Capsomer construction and vaccination
The generation of the HPV16 L1 deletion mutant (GST-
HPV16L1D) and its purification after expression as a GST fusion
protein in bacteria have been previously described [16]. A second
construct (GST-HPV16L1D-L2x3) was prepared for this study by
fusing a bacterial codon-optimized sequence encoding L2 amino
acids 13–47 of HPV18 with the corresponding sequences of
HPV31 and HPV45 in tandem to the C-terminus of GST-
HPV16L1D. Both constructs were used for the expression of high
levels of soluble protein in bacteria. These proteins were purified
from lysates by affinity FPLC chromatography with glutathione
sepharose. A ,5-fold lower dose of L1 as VLP compared to
capsomers is sufficient to induce immunity [19,32].Therefore, to
assess the immunogenicity of the GST-HPV16L1D and GST-
HPV16L1D-L2x3 capsomers, groups of Balb/c mice were
immunized three times at two-week intervals with 25 mgo f
capsomers formulated in 50 mg alum and 5 mg MPL per dose. For
comparison, an additional group of mice was vaccinated with 1/
10
th of a human dose of CervarixH, which was comprised of 2 mg
each of HPV16 and HPV18 L1 VLPs formulated in 50 mg alum
and 5 mg MPL.
Serum neutralization antibody titers
Two weeks after the third immunization, serum samples from
each immunized group were tested for neutralizing antibody titers
against the four HPV types most commonly found in cervical
cancer [33]. HPV16-specific serum neutralization titers were
detected in all groups of mice except for the naı ¨ve group (Figure 1).
Animals immunized with CervarixH showed a very high mean
serum titer of HPV16 neutralizing antibodies (53,120), whereas
the GST-HPV16-L1D and GST-HPV16-L1D-L2x3 capsomer-
immunized groups exhibited mean titers of 7520 and 6160,
respectively (Figure 1A), suggesting that the greater immunoge-
nicity of VLP may provide dose sparing as compared with
capsomers. However, the average anti-HPV18, HPV31 and
HPV45 neutralization titers were below the limit of detection
(,100) for both groups that received capsomer vaccines, which is
consistent with type-restricted neutralization (Figures 1B-D).
Serum samples from the CervarixH-immunized group exhibited
an average neutralization titer of 34,720 against HPV18, whereas
average neutralization titers against HPV31 and HPV45 were
below the limit of detection (,100). The latter finding is surprising
because vaccination with CervarixH protects patients against
HPV31 and HPV45 [6] and modest titers of neutralizing
antibodies for these types were detected in some vaccinated
patients [34], indicating that even very low titers of neutralizing
antibodies are protective.
Serum anti-HPV L2 ELISA titers
Serum samples from each immunized group taken two weeks
after the third immunization were tested for L2-specific antibody
titers by ELISA against either HPV16 L2 11–200 or HPV16 L2
17–36, conserved neutralizing and protective epitopes [24,35].
Sera of mice vaccinated with GST-HPV16L1D-L2x3 exhibited
mean ELISA titers of 545 and 230, respectively, against HPV16
L2 11–200 and 17–38 (Figure 2). Since the GST-HPV16L1D-
L2x3 contains L2 sequences derived from HPV18, 31 and 45, we
examined the reactivity of the sera to full length HPV18 L2
protein, HPV31 full length L2 protein and 17–36 peptide, and
HPV45 L2 16–35 peptide. The GST-HPV16L1D-L2x3 antisera
reacted specifically with the HPV18 and HPV45 L2 polypeptides,
but not with either the HPV31 full length protein or the 17–36
peptide. The GST-HPV16L1D-L2x3 antisera also failed to react
with HPV35 L2 17–36 or HPV58 L2 16–35 peptides, two types
that were not included in the vaccine construct.
We previously showed that the L1 and L2-specific antibody
responses to vaccination with L1 capsomers mixed with multi-
meric L2 protein 11-88x5 (a fusion of L2 amino acid residues 11–
88 derived from HPV1, 5, 6, 16 and 18) were independent (i.e., no
interference was noted) [21]. Although fusion of L2 with L1
capsomers did not significantly impact the neutralizing antibody
response, surprisingly, no neutralizing antibody titers were
detected for HPV18, HPV31 or HPV45, indicating that the L1-
specific response might dominate the L2-specific response to
GST-16L1D-L2x3 vaccination. GST-HPV16L1D-L2x3 is a fusion
peptide that contains GST, an L1 deletion mutant and three
copies of L2 amino acids 13 to 47 derived from HPV types 18, 31
and 45, while 11-88x5 is a fusion of L2 amino acids 11 to 88 from
five different HPV types (HPV1, 5, 6, 16 and 18) [36]. Thus,
vaccination with 4 mg of the latter would provide a similar amount
of L2 for comparison. Serum collected from mice immunized with
4 mg of 11-88x5 had a mean HPV16 L2 17–36 peptide ELISA
titer of 2960, which is <12-fold higher than the mean serum titer
Prophylactic Vaccination with HPV Capsomers
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As compared with GST-HPV16L1D-L2x3 antisera, the antisera to
the11-88x5fusion was alsomorecross-reactivewithL2neutralizing
epitopes of HPV types not utilized in making the 11-88x5 construct,
notably HPV31, HPV35, HPV45, and HPV58.
In vivo PsV vaginal challenge of capsomer-immunized
mice
Because vaccination with both capsomer vaccines elicited robust
HPV16 neutralizing antibody titers, the mice were subjected to
vaginal challenge with HPV16 pseudovirus carrying a luciferase
reporter to facilitate the measurement of infectivity in vivo. Three
days after intravaginal challenge with HPV16 PsV, the non-
immunized animals exhibited a high mean luciferase activity
(Figure 3A). Conversely, mice immunized with either GST-
HPV16L1D or GST-HPV16L1D-L2x3 exhibited background
levels of luciferase reporter gene activity similar to that of
CervarixH-immunized mice, which is consistent with complete
protection. The background luciferase levels in the mice
immunized with GST-HPV16L1D, GST-HPV16L1D-L2x3 or
CervarixH were not significantly different (Figure 3A).
Vaccination with GST-16L1D-L2x3 elicited L2-specific anti-
body responses, but no cross-neutralizing antibody responses were
detected for HPV18, HPV31 or HPV45. However, previous
studies indicate that the antibody levels necessary for protection
are low and that the current neutralization assay may lack
sensitivity for L2-specific neutralizing antibodies [37]. In order to
determine if vaccination with GST-HPV16L1D can induce
cross-protection, or if fusion of L2x3 to the C-terminus of GST-
HPV16L1D can enhance cross-protection, immunized mice
were vaginally challenged with HPV18. Despite us i n gag r e a t e r
c h a l l e n g ed o s eo fH P V 1 8P s V( 8 . 3mg of L1) than HPV16 PsV
(1 mg of L1), it is noteworthy that HPV16 PsV are dramati-
cally more infectious in mice than HPV18 PsV (Figure 3B).
Nevertheless, naı ¨ve mice exhibited a clear signal after HPV18
PsV challenge, while mice vaccinated with CervarixH that
contains HPV18 L1 VLPs, exhibited background levels, which
is consistent with complete protection (Figure 3B). Vaccination
with GST-HPV16L1D capsomers failed to provide significant
protection against HPV18 challenge, suggesting that capsomers,
like L1 VLPs, trigger a type-restricted protective immune
response. Conversely, vaccination with GST-16L1D-L2x3
provided robust protection against HPV18 challenge, which
was not significantly different from that achieved with
CervarixH (Figure 3B).
Discussion
Vaccination with GST-HPV16L1D was as effective as Cervar-
ixH in protecting mice against vaginal challenge with HPV16,
although inducing neutralizing antibody titers approximately
seven-fold lower than CervarixH. However a more optimized
capsomer formulation may reduce or negate this difference, and
the difference with GardasilH may be less [38]. It should be noted,
Figure 1. Neutralizing antibody responses of mice vaccinated with capsomers. Two weeks after the third immunization with GST-
HPV16L1D, GST-HPV16L1D-L2x3 or CervarixH, two-fold dilutions of serum from naı ¨ve or immunized mice were tested for in vitro neutralization activity
against pseudovirions derived from HPV16 (A), HPV18 (B), HPV31 (C) or HPV45 (D) starting at a dilution of 1:100. The reciprocal of the highest serum
dilution with $50% reduction in reporter gene expression signal was defined as the serum virus neutralizing antibody titer, and ,100 was
considered not detected (ND) and arbitrarily plotted at 10.
doi:10.1371/journal.pone.0027141.g001
Prophylactic Vaccination with HPV Capsomers
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27141Prophylactic Vaccination with HPV Capsomers
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27141however, that very low titers of antibodies appear to be sufficient
to protect mice from vaginal challenge [37], as illustrated by the
cross-protection of mice against HPV18 by vaccination with GST-
16L1D-L2x3. In this case, the mean titer of HPV18 neutralizing
antibodies was below the threshold of detection, yet a similar level
of protection was observed in mice vaccinated with CervarixH,
which exhibited very high titers of antibodies. It is possible that the
difficulty in detecting L2-specific protective antibodies reflects
differences in the exposure of L2 during in vitro infection of 293TT
cells as compared with in vivo infection of the genital mucosa,
or dramatically lower levels and/or avidity as compared to
L1-specific neutralizing antibodies. The presence of L2-reactive
antibodies in the sera of mice immunized with GST-HPV16L1D-
L2x3 was detectable at low titer by ELISA, suggesting the latter
possibility. The antibody responses to the conserved L2 neutral-
izing epitope comprising residues 17–36 [24] were approximately
12-fold lower in mice immunized with GST-HPV16L1D-L2x3 as
compared mice immunized with L2 11-88x5. This result suggests
that fusion of L2 with L1 does not enhance, and may compromise
the response to L2. When L2 is simply mixed with L1 capsomers,
no interference is observed [21], whereas L2 is subdominant to
L1 when they are co-assembled into VLPs [30]. Thus there are
several efforts to substitute the immunodominant L1 epitopes
with a cross-neutralizing L2 epitope to render L2 more immuno-
genic like L1 [39,40,41]. Because vaccination with GST-16L1D
protected against challenge with HPV16 but not HPV18 PsV, the
protection provided by L1 capsomers appears to be type-restricted
as seen for L1 VLPs, and exposure of the sides of the capsomers by
preventing assembly does not uncover cross-protective L1-specific
epitopes. Clearly, the alternate approach to achieve broad pro-
tection is to generate a highly multivalent L1 capsomer-based
vaccine, and capsomers have already been produced for HPV11,
HPV16, HPV18 and HPV35 [42]. Nevertheless, the fusion of an
L2 multimer to the C-terminus of L1 did not negatively impact the
L1 responses, and it provided broader protection.
The cost of manufacture remains a major, although not the
only, barrier to global implementation of HPV vaccines [2]. The
ability to produce very high yields of capsomers in a low cost
bacterial expression system suggests the potential for cost
reduction. The N-terminal deletion in L1 enhances production,
and fusion to GST facilitates capsomer purification. The C-
terminal deletion removes the arm that otherwise coordinates with
adjacent capsomers within a VLP as well as the L1 DNA-binding
domain, thereby obviating the need for disassembly/reassembly
to remove contaminating host DNA during VLP purification
[43,44,45].
Herein we examined the immunogenicity of L1 capsomers on
which the GST was retained. Although a tag such as GST would
typically be removed from an antigen being considered for clini-
cal application, the GST was retained because it has potential as
an anti-schistosome immunogen [46,47]. Schistosomiasis is the
second major parasitic disease after malaria and is an important
public health problem in many non-industrialized countries. Fur-
thermore urinary schistosomasis is a trigger for bladder cancer.
The GST used in this study for affinity purification is derived from
S. japonicum. GST derived from S. hematobium is currently in phase
III testing (clinicaltrials.gov; identifier NCT00870649) to examine
its value as a therapeutic vaccine (Bilhvax) in children exposed to
urinary schistosomiasis [47]. Therefore, the inclusion of GST in
the capsomer vaccine not only facilitates the purification process, it
also confers the potential to trigger immunity at low cost against
both papillomavirus and schistosome infections, two carcinogenic
infections that cause significant mortality and morbidity in
developing countries [12].
Figure 3. Vaginal challenge of mice with HPV PsV after
immunization with capsomers. Mice were subcutaneously immu-
nized with GST-HPV16L1D, GST-HPV16L1D-L2x3 or CervarixH three
times at two-week intervals. Three and five weeks after the last
immunization, the mice were challenged with either HPV16 (A) or
HPV18 (B) PsV carrying a luciferase reporter, respectively. Three days
after challenge, the mice received an intravaginal instillation of 20 mlo f
D-luciferin and were imaged with a Xenogen IVIS 100 system (image
captured for 10 min post-installation of luciferin). Image analysis in each
experiment was based on the average measurement (photons/s/cm
2)
collected from each selected equally-sized area (A, 1.9 cm
2; B, 0.6 cm
2)
in the vaginal tract.
doi:10.1371/journal.pone.0027141.g003
Figure 2. L2-specific antibody titers induced by vaccination of mice with capsomers. Two weeks after the third immunization with GST-
HPV16L1D, GST-HPV16L1D-L2x3 or CervarixH, two-fold dilutions of serum from immunized mice were tested by ELISA for L2 specific antibodies.
Microtiter plates were coated with either HPV16 L2 amino acids 11–200 (A), or the 17–38 L2 peptide (B), or HPV18 L2 full length protein (C), or HPV31
L2 17–36 peptide (D), or HPV31 full length protein (E) or HPV35 L2 17–36 peptide (F), or HPV45 L2 16–35 peptide (G), or HPV58 L2 16–35 peptide (H),
and then incubated with diluted serum samples (1:50 as the initial dilution; two-fold serial dilutions).
doi:10.1371/journal.pone.0027141.g002
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Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal studies were performed with the prior approval of the
Animal Care and Use Committee of Johns Hopkins University
(protocol MO08M19).
Cells, plasmids, media and growth conditions
Plasmid pGEX-HPV16 L1D (encoding amino acids 36–502
from GenPept accession number NP_041332.1) was constructed
for the expression of the deletion mutant HPV16 L1DN9DC29
with an N-terminal GST tag. The HPV16 L1 gene was codon
optimized for expression in Escherichia coli and synthesized by
Genscript with a BamHI site at its 59 end, and two stop codons
and an XhoI site at its 39 end. It was then cloned into the BamHI/
XhoI sites of pGEX-4T-2 (GE Healthcare) and verified by
sequencing.
Plasmid pGEX-HPV16 L1D-L2x3 was constructed by ampli-
fying HPV16 L1DN9DC29 from the aforementioned plasmid and
reinserting the L1 segment into pGEX-4T-2 using the BamHI and
EcoRI restriction sites. The L2 segment of this plasmid was
created synthetically using overlapping oligonucleotides that were
assembled and amplified using PCR. A sequence containing
amino acids 12–46 from HPV18 L2, amino acids 13–46 from
HPV31 L2 and amino acids 12–46 from HPV45 L2 (GenPept
accession numbers AAP20600.1, AAA92893.1 and AAY86493.1,
respectively) in tandem were submitted to the online program
DNAWorks (http://helixweb.nih.gov/dnaworks/). This sequence
also contained five glycines preceding the HPV18 L2 sequence
and two glycines in between the HPV18 and 31 and HPV31 and
45 sequences. The DNAWorks output included 16 oligonucleo-
tides optimized for expression in E. coli. These oligonucletoides
were assembled by PCR in a reaction containing 100 ng of each
oligo, 200 mM of each dNTP, 1x PfuTurbo reaction buffer and 2.5
U PfuTurbo (Stratagene). The assembly reaction was performed as
follows: 2 min at 95uC, 25 cycles of 30 sec at 95uC, 30 sec at 55–
65uC and 1 min at 72uC followed by 10 min at 72uC. Each of
these reactions (1 ml as a template) was then amplified using the
outermost oligonucleotides as forward and reverse primers (100 ng
each). The amplification reaction was performed as follows: 2 min
at 95uC, 25 cycles of 30 sec at 95uC, 30 sec at 62uC and 1 min at
72uC followed by 10 min at 72uC. The assembly reactions
performed between 60 and 65uC resulted in the appropriately
sized product. This product was digested and ligated into the
pGEX-4T-2 vector containing HPV16 L1D between the EcoRI
and NotI sites. The plasmid was verified by DNA sequencing.
Purification of capsomers
Truncated HPV16 L1 was expressed as a GST fusion protein
either alone or with the tandem HPV L2 epitopes in BL21(DE3)
E. coli (Stratagene). A single colony of transformed bacteria was
inoculated into 50 ml of Terrific Broth (TB) (1.2% Tryptone,
2.4% yeast extract, 0.5% glycerol, 17 mM KH2PO4 and 72 mM
K2HPO4) containing 100 mg/ml ampicillin and grown overnight
at 30uC. The 50 ml overnight culture was then used to inoculate
500 ml of fresh selection medium to an optical density (OD)595 of
0.1, and this culture was grown at 37uC until the OD595 reached
4.0. The temperature was decreased to 25uC, 200 ml of 0.5 M
IPTG was added and the culture was grown to an OD595 of 8. The
cultures were then split into two bottles of 250 ml each, and the
cells were harvested by centrifugation at 5000 rpm for 15 min at
4uC. The cell pellets were frozen at 220uC until use.
The cells were lysed, and the fusion proteins were purified via
affinity chromatography. Each cell pellet was resuspended in
100 ml of ice-cold buffer L (50 mM Tris-HCl pH 8.0, 0.2 M
NaCl, 1 mM EDTA) with 5 mM DTT, 1 mM PMSF and 1x
complete protease inhibitor cocktail (Roche). The cell suspension
was homogenized using a French pressure cell (Thermo Scientific)
at 2,000 psi to complete cell lysis. DNase I (40 U/ml), 2 mM ATP
and 10 mM MgCl2 were added to the lysed bacteria, and the
lysate was rocked for 1 h at room temperature. Solid urea was
then added to a final concentration of 2.3 M, and the lysate was
again rocked for 1 h at room temperature. The lysate was dialyzed
overnight at 4uC into two changes of buffer L/5 mM DTT
without urea, centrifuged at 25,0006g for 20 min at 4uC and
passed through a 0.2 mm filter. A volume of 50 ml of clarified
lysate was applied to a glutathione sepharose column (GSTrap FF
5 ml column, GE Healthcare) at 0.5 ml/min using an A ¨KTA
FPLC system (GE Healthcare). The column was washed with four
column volumes each of buffer L with 2 mM DTT and buffer L
with 2 mM DTT and 0.01% Tween 80. The GST-tagged proteins
were eluted with buffer L with 2 mM DTT, 0.01% Tween80
and 10 mM reduced glutathione. SDS-PAGE analysis of the
eluted fusion protein demonstrated GST-HPV16L1D or GST-
HPV16L1D-L2x3 and free GST as the major components. The
concentration of the GST-16L1D and GST-16L1D-L2x3 proteins
in the samples used for vaccination were estimated by SDS-PAGE
in comparison to BSA standards. The conformation of these
proteins was verified by ELISA with the H16.V5 antibody [48],
which specifically reacts with a conformationally-dependent
neutralizing epitope on the L1 surface.
Generation of HPV pseudoviruses (PsV)
Pseudoviruses were generated as previously described [49].
Briefly, plasmids pshellHPV16L1L2, pVitroHPV18L1L2, pVi-
troHPV31L1L2 or pVitroHPV45L1L2 were transfected with
either a luciferase or alkaline phosphatase (SEAP) reporter gene
plasmid into 293TT cells [49] using TransIT-2020 transfection
reagent (Mirus). Three days after transfection, cell pellets were
collected and rinsed with DMEM and Dulbecco’s PBS. The pellets
were resuspended in a small volume of DPBS-Mg (DPBS
supplemented with 9.5 mM MgCl2) and then transferred into
siliconized tubes. Cells were pelleted by low speed centrifugation,
and the supernatant was discarded. For PsV maturation, an equal
volume of lysis buffer (DPBS-Mg supplemented with 0.5% of Brij
58 and 0.2% benzonase) was added to the cell pellet, which was
allowed to incubate at 37uC for 24 h. After maturation, lysates
were adjusted to 850 mM NaCl and extracted with high salt buffer
(DPBS with 0.8 M NaCl). Lysates were clarified by centrifugation
at 10,0006g for 10 min, loaded onto an Optiprep step gradient
(27, 33 and 39%) and spun at 40,000 rpm in a SW40 rotor for
16 h at 16uC. After centrifugation, 0.5 ml fractions were collected
from the top of the gradient. A sample representing each fraction
was diluted and tested on 293TT cultures [49] for reporter gene
expression. Fractions with highest reporter gene expression were
pooled and used for the serum neutralization assay and the in vivo
challenge experiments.
Immunization of mice
Inbred 4- to 6-week old female BALB/c mice (NCI) in groups of
five or 10 were immunized subcutaneously three times at two-
week intervals. The immunogens used were 25 mg of GST-
HPV16L1D,2 5mg of GST-HPV16L1D-L2x3 or the indicated
doses of the 11-88x5 HPV L2 fusion peptide. Each dose of
Prophylactic Vaccination with HPV Capsomers
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aluminum hydroxide and 5 mg 3-O-desacyl-49-monophosphoryl
lipid A [MPL]) to 1/10
th of a human dose of the CervarixH
vaccine.
Measurement of neutralization antibody titers
Serum samples collected from each mouse two weeks after the
final immunization were serially diluted two-fold in culture
medium, mixed with an equal volume of HPV pseudovirions
containing either luciferase or SEAP reporter genes, and
incubated at 37uC for 2 h. These samples were each added to
293TT cell cultures (3610
4 cells/well), which were then incubated
for 72 h [49]. To measure luciferase expression, culture media
were removed from each well and 1x Cell Culture Lysis Reagent
(CCRL, Promega) was added to lyse the cell monolayer for 15 min
at room temperature on a rocking platform. A volume of 20 mlo f
the lysate from each well was transferred to a black microtiter plate
followed by the addition of 50 ml/well of 1x luciferase substrate
(Promega). The plates were scanned with the GloMaxH-Multi
Detection System (Promega). For SEAP measurement, 40 mlo f
cell-free supernatant was collected from each well, mixed with
20 ml of 0.05% CHAPS, heated at 65uC for 30 min and then
cooled on ice. A volume of 200 ml/well of p-nitrophenyl phosphate
(pNPP) substrate (2 M diethanolamine with 1 mg/ml of pNPP)
was added to each well for color development at ambient
temperature, and absorbance data was collected with an automatic
ELISA plate reader (Bio-Rad). Data was collected when the
absorbance from the wells incubated with only PsV (ODpsv) had
an OD405.1. The highest dilution of serum that resulted in 50%
or more reduction in ODpsv was defined as the endpoint
neutralization titer and expressed as its reciprocal value.
Determination of ELISA antibody titers
L2 antigens (HPV16 L2 amino acids 11–200 or full length
HPV18 L2 or HPV31 L2 were generated in E. coli as 6xHis fusions
[35], or L2 amino acids 17–38 of HPV16, 17–36 of HPV31, 17–
36 of HPV35, 16–35 of HPV45 or 16–35 of HPV58 chemically
synthesized as a peptide) were coated onto an ELISA plate
(MaxiSorp; Thermo Scientific) at 100 ng of protein or 500 ng of
peptide per well and incubated at 4uC overnight. Coated plates
were blocked with PBS-BSA (1x PBS supplemented with 1% BSA)
at 37uC for 1 h and then incubated with 100 ml of the diluted
serum samples (two-fold serial dilution from 1:50) at ambient
temperature for 1 h. Plates were then washed three times with
PBST (1x PBS with 0.01% Tween 20), and bound antibody was
detected with horseradish peroxide-conjugated sheep anti-mouse
IgG antibodies (GE Health) followed by further washes with PBST
and development with the 2,29-azinobis[3-ethylbenzothiazoline-6-
sulfonic acid]-diammonium salt (ABTS) substrate (Roche). The
cutoff OD value (ODcutoff) for the ELISA assay was set at three
times the average absorbance detected from five naı ¨ve mouse
serum samples. The highest dilution of serum sample that had an
OD value equal to or above the ODcutoff was defined as the
endpoint ELISA titer.
In vivo PsV vaginal challenge
Four days before challenge, female Balb/c mice were injected
subcutaneously with 3 mg of medroxyprogesterone (Depo-Pro-
vera; Pfizer) to synchronize their estrus cycles [50]. Each challenge
dose was comprised of 10 ml PsV mixed with 10 mlo f3 %
carboxymethyl cellulose (CMC). The dose was delivered twice into
vaginal vault, the first 10 ml just prior to and the second 10 ml just
after treatment with a cytobrush cell collector. The cytobrush cell
collector was inserted into the vaginal vault and turned both
counter-clockwise and clockwise 15 times while the mice were
anesthetized. Three days after PsV delivery, the mice were again
anesthetized and 20 ml of luciferin (7.8 mg/ml) was deposited in
the vaginal vault. Luciferase signals were acquired for 10 min with
a Xenogen IVIS 100 imager, and analysis was performed with
Living Image 2.0 software.
Statistical analysis
Data were analyzed with one-way ANOVA, or the Kruskal-
Wallis test and multiple comparison methods (GraphPad 4).
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